Currently, there are 226.06M common shares owned by the public and among those 225.14M shares have been available to trade.
The company’s stock has a 5-day price change of 6.18% and 75.55% over the past three months. ADMA shares are trading 306.64% year to date (YTD), with the 12-month market performance up to 376.17% higher. It has a 12-month low price of $3.06 and touched a high of $18.48 over the same period. ADMA has an average intraday trading volume of 3.52 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 6.46%, 28.45%, and 120.46% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Adma Biologics Inc (NASDAQ: ADMA) shares accounts for 77.86% of the company’s 226.06M shares outstanding.
It has a market capitalization of $4.28B and a beta (3y monthly) value of 0.63. The stock’s trailing 12-month PE ratio is 130.73, while the earnings-per-share (ttm) stands at $0.14. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.16% over the week and 4.83% over the month.
Earnings per share for the fiscal year are expected to increase by 471.15%, and 35.75% over the next financial year.
Looking at the support for the ADMA, a number of firms have released research notes about the stock. Raymond James stated their Strong Buy rating for the stock in a research note on July 19, 2023, with the firm’s price target at $5. Mizuho coverage for the Adma Biologics Inc (ADMA) stock in a research note released on October 13, 2022 offered a Buy rating with a price target of $5. Raymond James was of a view on November 11, 2021 that the stock is Strong Buy, while Cantor Fitzgerald gave the stock Overweight rating on November 09, 2021, issuing a price target of $4.50. Jefferies on their part issued Buy rating on June 04, 2019.
